The renoprotective effects of berberine via the EP4-Gαs-cAMP signaling pathway in different stages of diabetes in rats

References

• Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 2006;6:479–83
   PubMedGoogle Scholar
• Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005;16:S30–3
   PubMed Web of Science ®Google Scholar
• Kanwar YS, Akagi S, Sun L, et al. Cell biology of diabetic kidney disease. Nephron Exp Nephrol 2005;101:e100–10
   Google Scholar
• Suleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007;59:247–58
   PubMed Web of Science ®Google Scholar
• Fujino H, Xu W, Regan JW. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003;278:12151–6
   PubMed Web of Science ®Google Scholar
• Jensen BL, Mann B, Skott O, et al. Differential regulation of renal prostaglandin receptor mRNAs by dietary salt intake in the rat. Kidney Int 1999;56:528–37
   Google Scholar
• Aoudjit L, Potapov A, Takano T. Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor. Am J Physiol Renal Physiol 2006;290:F1534–42
   Google Scholar
• Stitt-Cavanagh EM, Faour WH, Takami K, et al. A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 2010;21:1678–90
   PubMed Web of Science ®Google Scholar
• Nakagawa N, Yuhki K, Kawabe J, et al. The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice. Kidney Int 2012;82:158–71
   Google Scholar
• Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metab Clin Exp 2008;57:712–17
   PubMed Web of Science ®Google Scholar
• Yin J, Gao Z, Liu D, et al. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol 2008;294:E148–E56
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006;55:2256–64
   PubMed Web of Science ®Google Scholar
• Yin J, Zhang H, Ye J. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008;8:99–111
   PubMedGoogle Scholar
• Liu WH, Hei ZQ, Nie H, et al. Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase. Chin Med J 2008;121:706–12
   PubMed Web of Science ®Google Scholar
• Tang LQ, Lv F, Liu S, et al. Effect of berberine on expression of transforming growth factor-b1 and FN proteins in mesangial cells of diabetic rats with nephropathy. Chin J Chin Mater Med 2011;36:3494–7
   Google Scholar
• Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008;93:2559–65
   PubMed Web of Science ®Google Scholar
• Xie X, Chang XT, Chen L, et al. Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting the activation of RhoA/ROCK signaling. Mol Cell Endocrinol 2013;381:56–65
   PubMed Web of Science ®Google Scholar
• Domitrović R, Cvijanović O, Pernjak-Pugel E, et al. Berberine exerts nephroprotective effect against cisplatin-induced kidney damage through inhibition of oxidative/nitrosative stress, inflammation, autophagy and apoptosis. Food Chem Toxicol 2013;62C:397–406
   Google Scholar
• Liu S, Tang LQ, Chen LM. Study on extraction technology of berberine from Rhizoma coptidis by the method of orthogonal-test optimization. China Pharmacy 2004;15:18–20
   Google Scholar
• Zhang JT. Modern experimental methods in pharmacology. Beijing: Beijing Medical University; 1998:982
   Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223–33
   PubMed Web of Science ®Google Scholar
• Vladimirova-Kitova LG, Deneva TI. Simvastatin and asymmetric dimethylarginine-homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia. Clin Lab 2010;56:291–302
   PubMed Web of Science ®Google Scholar
• Xu XX, Zhang W, Zhang P, et al. Superior renoprotective effects of the combination of breviscapine with enalapril and its mechanism in diabetic rats. Phytomedicine 2013;20:820–7
   PubMed Web of Science ®Google Scholar
• Itoh Y, Imamura S, Yamamoto K, et al. Changes of endothelin in streptozotocin-induced diabetic rats: effects of an angiotensin converting enzyme inhibitor, enalapril maleate. J Endocrinol 2002;175:233–9
   Google Scholar
• Yang F, Tang LQ, Wang FL, et al. Study of the influential factor on the establishment of experimental diabetic nephropathy in rats. Anhui Med Pharm J 2011;16:735–8
   Google Scholar
• Danda RS, Habiba NM, Rincon-Choles H, et al. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int 2005;68:2562–71
   PubMed Web of Science ®Google Scholar
• Thompson J, Wilson P, Brandewie K, et al. Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol 2011;179:1179–87
   PubMed Web of Science ®Google Scholar
• Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260–9
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xiao X, Feng K, et al. Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evid Based Complement Alternat Med 2011;2011
   Google Scholar
• Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 2008;70:357–77
   PubMed Web of Science ®Google Scholar
• Purdy KE, Arendshorst WJ. EP(1) and EP(4) receptors mediate prostaglandin E(2) actions in the microcirculation of rat kidney. Am J Physiol Renal Physiol 2000;279:F755–64
   Google Scholar
• Schweda F, Klar J, Narumiya S, et al. Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. Am J Physiol Renal Physiol 2004;287:F427–33
   Google Scholar
• Nagamatsu T, Imai H, Yokoi M, et al. Protective effect of prostaglandin EP4-receptor agonist on anti-glomerular basement membrane antibody-associated nephritis. J Pharmacol Sci 2006;102:182–8
   Google Scholar
• Nagamatsu T, Imai H, Yokoi M, et al. Protective effect of prostaglandin EP4-receptor agonist on anti-glomerular basement membrane antibody-associated nephritis. J Pharmacol Sci 2006;102:182–8
   Google Scholar
• Aoudjit L, Potapov A, Takano T. Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor. Am J Physiol Renal Physiol 2006;290:F1534–42
   Google Scholar
• Yamamoto E, Izawa T, Juniantito V, et al. Involvement of endogenous prostaglandin E2 in tubular epithelial regeneration through inhibition of apoptosis and epithelial-mesenchymal transition in cisplatin-induced rat renal lesions. Histol Histopathol 2010;25:995–1007
   PubMedGoogle Scholar
• Liu Y, Rajagopal M, Lee K, et al. Prostaglandin E(2) mediates proliferation and chloride secretion in ADPKD cystic renal epithelia. Am J Physiol Renal Physiol 2012;303:F1425–34
   Google Scholar
• Wu J, Zhang Y, Frilot N, et al. Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. J Biol Chem 2011;286:33954–62
   Google Scholar